Focus: Grifols is a global biopharmaceutical company specializing in diagnostics and plasma-derived therapeutics, headquartered in New York with a public listing on GIKLY. The company operates across rare diseases, immunology, and hemostasis with a portfolio spanning diagnostics, immunoglobulins, and clotting factors.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Grifols to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Commodity injectable with minimal differentiation; sustaining revenue base only.
Help build intelligence for Grifols
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Grifols's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Plasma machine at Grifols collection centre issued five alerts before Winnipeg donor’s death - The Globe and Mail
Plasma machine at Grifols collection centre issued five alerts before Winnipeg donor’s death The Globe and Mail
Grifols lays the first stone of the new plant in Lliçà de Vall - Diari ARA
Grifols lays the first stone of the new plant in Lliçà de Vall Diari ARA
Family of plasma donor who died calls for investigation over record inconsistencies - The Globe and Mail
Family of plasma donor who died calls for investigation over record inconsistencies The Globe and Mail
The market punishes Grifols despite quarterly profits - Diari ARA
The market punishes Grifols despite quarterly profits Diari ARA
8-K Filing: FrontView REIT, Inc. (FVR) (CIK 0001988494) — EX-99.2
EX-99.2
8-K Filing: QuidelOrtho Corp (QDEL) (CIK 0001906324) — EX-99.1
EX-99.1
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Hereditary Antithrombin Deficiency in Pediatric Patients: Pathophysiology, Clinical Features, Diagnosis, and Antithrombin Replacement Therapy.
Efficacy and safety of fibrinogen concentrate (BT524) in severe hemorrhage: Phase 3 subcohort analysis of the AdFIrst trial in patients undergoing cytoreductive surgery for pseudomyxoma peritonei.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo